Syngene Int. - Syngene International Share Price

  • 630.10-23.30 (-3.57%)
  • Volume: 44,15,736
  • Closed
  • Last Updated On: 25 Apr, 2025, 03:59 PM IST
Loading...

Syngene Int. - Syngene International Share Price

  • 630.10-23.30 (-3.57%)
  • Volume: 44,15,736
Advertisment
Stock Recommendations
  • Potential
    Upside

  • 1 Year
    Target

BUY

Mean Recos by
10 Analysts

0

3

1

4

2

Strong Sell

Sell

Hold

Buy

Strong Buy

Unlock Potential Upside
Stock Reports Plus

/10

Stock Score

View Report
Earnings
Fundamentals
Relative Valuation
Risk
Price Momentum
No Rating (NR)
Negative
Neutral
Positive
Unlock Stock Score

Syngene Int. share price insights

  • Meeting Agenda: Audited Results & Final Dividend. Please add to watchlist to track closely.

  • Company has spent 1.46% of its operating revenues towards interest expenses and 27.01% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)

  • Syngene International Ltd. share price moved down by -3.57% from its previous close of Rs 653.40. Syngene International Ltd. stock last traded price is 630.10

    Share PriceValue
    Today/Current/Last630.10
    Previous Day653.40653.85

InsightsSyngene Int.

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Key Metrics

    PE Ratio
    (x)
    51.12
    EPS - TTM
    (₹)
    12.33
    MCap
    (₹ Cr.)
    25,363.86
    Sectoral MCap Rank
    20
    PB Ratio
    (x)
    6.18
    Div Yield
    (%)
    0.20
    Face Value
    (₹)
    10.00
    Beta

    Beta

    1 Month0.40
    3 Months0.89
    6 Months0.59
    1 Year0.56
    3 Years0.69
    0.40
    VWAP
    (₹)
    637.57
    52W H/L
    (₹)
    960.60 / 607.65

    Syngene Int. Share Price Returns

    1 Day-3.57%
    1 Week-13.33%
    1 Month-11.78%
    3 Months-20.85%
    1 Year-9.87%
    3 Years-0.51%
    5 Years105.51%

    ET Stock ScreenersTop Score Companies

    Check whether Syngene Int. belongs to analysts' top-rated companies list?

    View Stock Screeners

    Syngene Int. Share Recommendations

    Recent Recos

    BUY

    Current

    Mean Recos by 10 Analysts

    Strong
    Sell
    SellHoldBuyStrong
    Buy
    • Target₹880
    • OrganizationIIFL
    • BUY
    • Target₹642
    • OrganizationHDFC Securities
    • BUY

    Analyst Trends

    RatingsCurrent1 Week Ago1 Month Ago3 Months Ago
    Strong Buy2211
    Buy4443
    Hold1111
    Sell3333
    Strong Sell----
    # Analysts101098

    Syngene Int. Financials

    • Insights

      • Employee & Interest Expense

        Company has spent 1.46% of its operating revenues towards interest expenses and 27.01% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)
      Quarterly | AnnualMar 2025Dec 2024Sep 2024Jun 2024Mar 2024
      Total Income1,036.90962.00907.50807.80933.00
      Total Income Growth (%)7.796.0112.34-13.425.69
      Total Expenses780.50768.80757.10694.80711.10
      Total Expenses Growth (%)1.521.558.97-2.29-3.09
      EBIT256.40193.20150.40113.00221.90
      EBIT Growth (%)32.7128.4633.10-49.0848.93
      Profit after Tax (PAT)183.30131.10106.1075.70188.60
      PAT Growth (%)39.8223.5640.16-59.8669.15
      EBIT Margin (%)24.7320.0816.5713.9923.78
      Net Profit Margin (%)17.6813.6311.699.3720.21
      Basic EPS (₹)4.563.272.641.894.70
      Quarterly | AnnualMar 2025Dec 2024Sep 2024Jun 2024Mar 2024
      Total Income966.80895.10837.70744.20880.00
      Total Income Growth (%)8.016.8512.56-15.437.23
      Total Expenses728.00718.60706.40638.00661.10
      Total Expenses Growth (%)1.311.7310.72-3.49-4.15
      EBIT238.80176.50131.30106.20218.90
      EBIT Growth (%)35.3034.4223.63-51.4867.10
      Profit after Tax (PAT)174.40123.1096.6073.90189.80
      PAT Growth (%)41.6727.4330.72-61.0690.18
      EBIT Margin (%)24.7019.7215.6714.2724.88
      Net Profit Margin (%)18.0413.7511.539.9321.57
      Basic EPS (₹)4.343.072.411.844.73
      Quarterly | Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Revenue3,714.203,579.203,263.802,657.002,248.90
      Total Revenue Growth (%)3.779.6622.8418.157.42
      Total Expenses3,086.302,947.302,670.202,141.901,814.70
      Total Expenses Growth (%)4.7210.3824.6718.0310.12
      Profit after Tax (PAT)496.20510.00464.40395.80404.90
      PAT Growth (%)-2.719.8217.33-2.25-1.75
      Operating Profit Margin (%)18.6919.4620.0020.7021.14
      Net Profit Margin (%)13.6214.6114.5415.1918.53
      Basic EPS (₹)12.3512.7111.599.9410.18
      Quarterly | Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Revenue3,443.803,291.103,264.402,654.202,244.00
      Total Revenue Growth (%)4.640.8222.9918.287.19
      Total Expenses2,854.202,722.702,663.502,141.801,811.60
      Total Expenses Growth (%)4.832.2224.3618.239.85
      Profit after Tax (PAT)468.00466.50473.00393.80403.70
      PAT Growth (%)0.32-1.3720.11-2.45-1.90
      Operating Profit Margin (%)18.4018.6620.2320.6221.11
      Net Profit Margin (%)13.8714.5614.8115.1318.52
      Basic EPS (₹)11.6411.6211.819.8910.15

      All figures in Rs Cr, unless mentioned otherwise

    • Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Assets6,795.906,151.605,831.005,563.804,883.20
      Total Assets Growth (%)10.475.504.8013.9417.30
      Total Liabilities2,069.101,893.802,213.002,266.202,061.80
      Total Liabilities Growth (%)9.26-14.42-2.359.913.76
      Total Equity4,726.804,257.803,618.003,297.602,821.40
      Total Equity Growth (%)11.0217.689.7216.8829.67
      Current Ratio (x)1.641.712.041.801.59
      Total Debt to Equity (x)0.030.030.160.240.27
      Contingent Liabilities0.00837.20805.50664.10595.50
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Assets6,406.905,833.905,848.005,560.804,877.50
      Total Assets Growth (%)9.82-0.245.1614.0117.19
      Total Liabilities1,768.001,642.402,229.102,268.802,059.20
      Total Liabilities Growth (%)7.65-26.32-1.7510.183.59
      Total Equity4,638.904,191.503,618.903,292.002,818.30
      Total Equity Growth (%)10.6715.829.9316.8129.63
      Current Ratio (x)1.531.692.111.791.59
      Total Debt to Equity (x)0.020.030.160.240.27
      Contingent Liabilities0.00798.70805.50664.10595.50

      All figures in Rs Cr, unless mentioned otherwise

    • Insights

      • Increase in Cash from Investing

        Company has used Rs 744.7 cr for investing activities which is an YoY increase of 50.26%. (Source: Consolidated Financials)
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Net Cash flow from Operating Activities1,167.601,042.10823.50580.60701.20
      Net Cash used in Investing Activities-744.70-495.60-656.40-611.50-628.10
      Net Cash flow from Financing Activities-141.80-551.40-342.50-31.3058.00
      Net Cash Flow281.40-3.80-172.30-61.50130.30
      Closing Cash & Cash Equivalent367.1085.7089.50261.80323.30
      Closing Cash & Cash Equivalent Growth (%)328.35-4.25-65.81-19.0267.51
      Total Debt/ CFO (x)0.100.140.701.361.10
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Net Cash flow from Operating Activities1,113.80913.40838.40582.20698.00
      Net Cash used in Investing Activities-810.40-383.50-688.20-611.50-628.10
      Net Cash flow from Financing Activities-136.50-536.30-340.20-31.3058.00
      Net Cash Flow166.90-5.50-186.90-59.90127.10
      Closing Cash & Cash Equivalent233.5066.6072.10259.00318.90
      Closing Cash & Cash Equivalent Growth (%)250.60-7.63-72.16-18.7866.27
      Total Debt/ CFO (x)0.090.160.691.361.11

      All figures in Rs Cr, unless mentioned otherwise

    • Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Return on Equity (%)10.4911.9712.8312.0014.35
      Return on Capital Employed (%)12.6113.5613.7512.4312.31
      Return on Assets (%)7.308.297.967.118.29
      Interest Coverage Ratio (x)20.9723.4122.2435.2226.58
      Asset Turnover Ratio (x)0.560.580.560.500.48
      Price to Earnings (x)59.1755.5651.5560.6153.76
      Price to Book (x)6.186.636.607.257.70
      EV/EBITDA (x)25.6425.1523.7828.5029.69
      EBITDA Margin (%)30.5731.6731.4832.5933.71
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Return on Equity (%)10.0811.1213.0711.9614.32
      Return on Capital Employed (%)12.2212.6214.4212.3912.27
      Return on Assets (%)7.307.998.087.088.27
      Interest Coverage Ratio (x)31.6732.7722.2435.1126.52
      Asset Turnover Ratio (x)0.550.550.560.500.48
      Price to Earnings (x)62.5060.6150.5160.9854.05
      Price to Book (x)6.306.736.597.277.71
      EV/EBITDA (x)29.0228.7823.8128.6029.77
      EBITDA Margin (%)29.2930.1831.4732.5233.70

    Financial InsightsSyngene Int.

    • Income (P&L)
    • Cash Flow
      • Employee & Interest Expense

        Company has spent 1.46% of its operating revenues towards interest expenses and 27.01% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)

      • Increase in Cash from Investing

        Company has used Rs 744.7 cr for investing activities which is an YoY increase of 50.26%. (Source: Consolidated Financials)

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Syngene Int. Share Price Forecast

    • Get multiple analysts’ prediction on Syngene Int.

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL
    • Get multiple analysts’ prediction on Syngene Int.

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL
    • Get multiple analysts’ prediction on Syngene Int.

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    Syngene Int. Technicals

    • Stock doesn't have any Buy/Sell Signals.

    • 45%
      Positive Movement since
      1st Jan 2005 on basis
      55%
      Negative Movement since
      1st Jan 2005 on basis
      Exclude
    • Pivot Levels

      R1R2R3PIVOTS1S2S3
      Classic648.73667.37696.37638.37619.73609.37580.37

      Average True Range

      5 DAYS14 DAYS28 DAYS
      ATR35.4028.3025.94

    Syngene Int. Peer Comparison

      • 1D
      • 1W
      • 1M
      • 3M
      • 6M
      • 1Y
      • 5Y
      Loading...
    • Ratio Performance

      NAMEP/E (x)P/B (x)ROE %ROCE %ROA %Rev CAGR [3Yr]OPMNPMBasic EPSCurrent RatioTotal Debt/ Equity (x)Total Debt/ CFO (x)
      Syngene Int.51.125.3710.4912.617.3011.6918.6913.6212.351.640.030.10
      Laurus Labs94.168.203.907.941.911.548.313.332.981.230.613.77
      Ajanta Pharma37.239.3722.8729.9517.5913.6226.6319.3964.823.050.000.00
      Suven Pharma 104.2214.1914.6419.2413.322.8039.2928.5611.8011.820.020.11
      Piramal Pharma737.003.620.225.760.118.727.72-0.500.141.250.584.54
      Add More
      Annual Ratios (%)

      Choose from Peers

      • J B Chemicals
      • Gland Pharma
      • Wockhardt
      • Emcure Pharmaceuticals Ltd.
      • Concord Biotech Ltd.

      Choose from Stocks

      Peers InsightsSyngene Int.

        Do you find these insights useful?

        • hate it

        • meh

        • love it

        Syngene Int. Shareholding Pattern

        • Loading...
          Showing Syngene Int. Shareholding as on Mar 2025
          CategoryMar 2025Dec 2024Sep 2024Jun 2024
          Promoters52.7452.7454.7254.72
          Pledge0.000.000.000.00
          FII19.4720.6520.7220.64
          DII21.5019.5217.4916.75
          Mutual Funds17.8615.4013.5813.63
          Others6.287.097.077.89
        • Showing Shareholding as on Mar 2025
          CategoryNo. of SharesPercentage% Change QoQ
          Promoters21,22,83,69752.74 %0.00
          Pledge00.00 %0.00
          FII7,83,69,04019.47 %-1.17
          DII8,65,57,05521.50 %1.98
          MF7,19,09,53117.86 %2.45
          Others2,53,27,1896.28 %-0.80

        Syngene Int. MF Ownership

        MF Ownership as on 31 March 2025

        Syngene Int. Corporate Actions

        • Meeting DateAnnounced onPurposeDetails
          Jul 23, 2025Apr 23, 2025AGM-
          Apr 23, 2025Apr 08, 2025Board MeetingAudited Results & Final Dividend
          Jan 23, 2025Jan 13, 2025Board MeetingQuarterly Results
          Oct 23, 2024Oct 04, 2024Board MeetingQuarterly Results
          Jul 24, 2024Jun 28, 2024Board MeetingQuarterly Results
        • TypeDividendDividend per ShareEx-Dividend DateAnnounced on
          Final12%1.25Jun 28, 2024Apr 24, 2024
          Final5%0.5Jun 30, 2023Apr 26, 2023
          Special5%0.5Jun 30, 2022Apr 28, 2022
          Final5%0.5Jun 30, 2022Apr 27, 2022
          Final12%1.25-Apr 23, 2025
        • All TypesEx-DateRecord DateAnnounced onDetails
          BonusJun 11, 2019Jun 12, 2019Apr 24, 2019Bonus Ratio: 1 share(s) for every 1 shares held

        About Syngene Int.

        Syngene International Ltd., incorporated in the year 1993, is a Mid Cap company (having a market cap of Rs 25,363.86 Crore) operating in Pharmaceuticals sector. Syngene International Ltd. key Products/Revenue Segments include Contract Research & Contract Manufacturing (CRAMS), Other Operating Revenue and Scrap for the year ending 31-Mar-2024. Show More

        • Executives

        • Auditors

        • KM

          Kiran Mazumdar Shaw

          Non Executive Chairman
          JH

          Jonathan Hunt

          Managing Director & CEO
          SB

          Sibaji Biswas

          Executive Director & CFO
          CR

          Catherine Rosenberg

          Non Executive Director
          Show More
        • B S R & Co. LLP

        FAQs about Syngene Int. share

        • 1. What's the Syngene Int. share price today?
          Syngene Int. share price is Rs 630.10 as on 25 Apr, 2025, 03:59 PM IST. Syngene Int. share price is down by 3.57% based on previous share price of Rs 749.15. Syngene Int. share price trend:
          • Last 1 Month: Syngene Int. share price moved down by 11.78%
          • Last 3 Months: Syngene Int. share price moved down by 20.85%
          • Last 3 Years: Syngene Int. Share price moved down by 0.51%
        • 2. What is the CAGR of Syngene Int.?
          The CAGR of Syngene Int. is 12.42.
        • 3. What is the PE & PB ratio of Syngene Int.?
          The PE ratio of Syngene Int. stands at 53.01, while the PB ratio is 6.17.
        • 4. What are the key metrics to analyse Syngene Int. Share Price?
          Syngene Int. share can be quickly analyzed on following metrics:
          • Stock's PE is 51.12
          • Price to Book Ratio of 6.18
        • 5. Who's the chairman of Syngene Int.?
          Kiran Mazumdar Shaw is the Non Executive Chairman of Syngene Int.
        • 6. What is 52 week high/low of Syngene Int. share price?
          In last 52 weeks Syngene Int. share had a high price of Rs 960.60 and low price of Rs 607.65
        • 7. What is the market cap of Syngene Int.?
          Within the Pharmaceuticals sector, Syngene Int. stock has a market cap rank of 20. Syngene Int. has a market cap of Rs 25,363.86 Cr.
        • 8. Who are the key owners of Syngene Int. stock?
          Promoter, DII and FII owns 52.74, 19.52 and 20.65 shares of Syngene Int. as on 31 Mar 2025
          • There is no change in promoter holding from 31 Dec 2024 to 31 Mar 2025
          • Domestic Institutional Investors holding has gone up from 19.52 (31 Dec 2024) to 21.5 (31 Mar 2025)
          • Foreign Institutional Investors holding have gone down from 20.65 (31 Dec 2024) to 19.47 (31 Mar 2025)
          • Other investor holding have gone down from 7.09 (31 Dec 2024) to 6.28 (31 Mar 2025)
        • 9. Who are the peers for Syngene Int. in Pharmaceuticals sector?
          Top 10 Peers for Syngene Int. are Suven Pharmaceuticals Ltd., Piramal Pharma Ltd., Wockhardt Ltd., J B Chemicals & Pharmaceuticals Ltd., Ajanta Pharma Ltd., Laurus Labs Ltd., Gland Pharma Ltd., Concord Biotech Ltd., Emcure Pharmaceuticals Ltd. and Natco Pharma Ltd.
        • 10. What are the Syngene Int. quarterly results?
          Total Revenue and Earning for Syngene Int. for the year ending 2025-03-31 was Rs 3714.20 Cr and Rs 496.20 Cr on Consolidated basis. Last Quarter 2025-03-31, Syngene Int. reported an income of Rs 1036.90 Cr and profit of Rs 183.30 Cr.
        • 11. Who is the Chief Executive Officer of Syngene Int.?
          Jonathan Hunt is the Managing Director & CEO of Syngene Int.
        • 12. What are the returns for Syngene Int. share?
          Return Performance of Syngene Int. Shares:
          • 1 Week: Syngene Int. share price moved down by 13.33%
          • 1 Month: Syngene Int. share price moved down by 11.78%
          • 3 Month: Syngene Int. share price moved down by 20.85%
        • 13. Is Syngene Int. giving dividend?
          An equity Final dividend of Rs 1.25 per share was declared by Syngene International Ltd. on 24 Apr 2024. So, company has declared a dividend of 12% on face value of Rs 10 per share. The ex dividend date was 28 Jun 2024.

        Trending in Markets

        Top Gainers As on 03:59 PM | 25 Apr 2025

        Waaree Energies2,676.50
        353.50 (15.22%)
        Au Small Fin Bank675.15
        88.60 (15.11%)
        Tata Elxsi5,612.50
        712.00 (14.53%)
        Newgen Software1,055.65
        129.55 (13.99%)
        Apar Industries5,539.50
        637.00 (12.99%)

        Top Losers As on 03:59 PM | 25 Apr 2025

        Blue Star1,739.20
        -276.20 (-13.70%)
        Syngene Int.630.10
        -96.90 (-13.33%)
        Phillips Carbon387.00
        -47.20 (-10.87%)
        Ramkrishna Forg656.70
        -79.80 (-10.84%)
        Caplin Point1,806.70
        -160.40 (-8.15%)

        DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

        DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

        By using this site, you agree to the Terms of Service and Privacy Policy.

        The Economic Times